Oppenheimer lowered the firm’s price target on BridgeBio (BBIO) to $81 from $83 and keeps an Outperform rating on the shares. The firm notes Q4 Attruby net sales were $146M as pre-announced, with modest contributions from royalties. Updated total script volume was encouraging, suggesting continued acceleration to start the year, Oppenheimer adds. Following the deluge of updates in 2026, the firm expects the stock to largely be powered by Attruby sales this year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside
- BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation
- BridgeBio reports Q4 EPS ($1.00), consensus (67c)
- BridgeBio off lows as traders discuss conference appearance
- BridgeBio price target raised to $100 from $90 at H.C. Wainwright